Table 3.
Raw data and pooled estimates of case fatality ratios (CFR) from studies stratifying by HIV-status. Includes children aged 0–14 years with known HIV test result.
| Study | Time period | HIV-uninfected children | HIV-uninfected deaths | HIV-uninfected CFR % (95% CI) | HIV-infected children | HIV-infected deaths | HIV-infected CFR % (95% CI) | P-value for difference between HIV-infected CFR and HIV-uninfected CFR2 |
|---|---|---|---|---|---|---|---|---|
| Minion et al. (Canada) | 2005–2012 | 71 | 2 | 2.8% (0.3%, 9.8%) | 3 | 0 | 0.0% (0.0%, 70.8%) | <0.99 |
| Erkens et al. (Netherlands) | 2005–2012 | 74 | 0 | 0.0% (0.0%, 4.9%) | 3 | 0 | 0.0% (0.0%, 70.8%) | <0.99 |
| Shah et al.1 (USA) | 1993–1996 | 679 | 8 | 1.2% (0.5%, 2.3%) | 77 | 11 | 14.3% (7.4%, 24.1%) | 0.0001 |
| 1997–2011 | 3831 | 17 | 0.4% (0.3%, 0.7%) | 88 | 3 | 3.4% (0.7%, 9.6%) | 0.0095 |
1
Data are presented separately for 1993–1996 and 1997–2011 because highly active antiretroviral therapy including protease inhibitors for treatment of HIV became the standard of care in the United States in 199764. Therefore, children during the earlier period were unlikely to be receiving antiretroviral therapy, while those in the later period would have had access to antiretroviral therapy.
2
P-values calculated using Fisher’s exact test